- The European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion backing Orphan Drug status for Geron's (NASDAQ:GERN) imetelstat for the treatment of myelodysplastic syndromes, a rare group of bone marrow failure disorders.
- Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, if approved.
- Shares up 3% premarket on modest volume.
Geron poised to nab Orphan Drug tag in Europe for imetelstat for bone marrow disorder
Recommended For You
About GERN Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| GERN | - | - |
| Geron Corporation | ||